Xeltis raises €27 million for pulmonary valve

A medical device which is intended to treat congenital malformations of the heart using a regenerative medicine approach has been backed by a syndicate of leading European investors in a €27 million Series B financing round.

Go to the profile of Victoria English
Dec 05, 2014
1
0

A medical device which is intended to treat congenital malformations of the heart using a regenerative medicine approach has been backed by a syndicate of leading European investors in a €27 million Series B financing round.

The device has been developed by Xeltis AG, a privately-held company based in Zurich, Switzerland. It is based on technology that is designed to stimulate and guide the body’s natural healing response from the inside. The device is a replacement pulmonary valve made from synthetic biodegradable materials. After implantation, it is expected to lead to the spontaneous growth of new valves and vessels. The company is investigating the device for the orphan paediatric indication of severe congenital malformations of the heart. The technology is still undergoing preclinical and clinical testing.

Leading the Series B round were Life Sciences Partners in Amsterdam, the Netherlands and Kurma Partners in Paris, France. VI Partners in Zug, Switzerland and current shareholders, also participated in the round.

Xeltis announced the financing on 2 December 2014.

Copyright 2014 Evernow Publishing Ltd

Go to the profile of Victoria English

Victoria English

Editor, MedNous, a publication of Evernow Publishing Ltd

Co-founder and editor of Evernow Publishing Ltd. International journalist with previous full-time editorial positions at Informa Plc, Thomson Reuters, McGraw-Hill and Dow Jones Inc. Have worked as a correspondent covering finance in New York, Amsterdam, Brussels and London, and covering healthcare and the life sciences in London.

No comments yet.